345 related articles for article (PubMed ID: 23273967)
1. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.
; Altmann D; Aseffa A; Bash M; Basta N; Borrow R; Broome C; Caugant D; Clark T; Collard JM; Djingarey M; Goldblatt D; Greenwood B; Griffiths U; Hajjeh R; Hassan-King M; Hugonnet S; Kimball AM; LaForce M; MacLennan C; Maiden MC; Manigart O; Mayer L; Messonnier N; Moisi J; Moore K; Moto DD; Mueller J; Nascimento M; Obaro S; Ouedraogo R; Page AL; Perea W; Pluschke G; Preziosi MP; Sow S; Stephens D; Stuart J; Thomson M; Tiendrebeogo S; Trape JF; Vernet G
Vaccine; 2013 Mar; 31(11):1453-7. PubMed ID: 23273967
[TBL] [Abstract][Full Text] [Related]
2. Meningococcal carriage in the African meningitis belt.
MenAfriCar Consortium
Trop Med Int Health; 2013 Aug; 18(8):968-78. PubMed ID: 23682910
[TBL] [Abstract][Full Text] [Related]
3. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
[TBL] [Abstract][Full Text] [Related]
4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
[TBL] [Abstract][Full Text] [Related]
5. Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine.
Topaz N; Kristiansen PA; Schmink S; Congo-Ouédraogo M; Kambiré D; Mbaeyi S; Paye M; Sanou M; Sangaré L; Ouédraogo R; Wang X
Microb Genom; 2020 Dec; 6(12):. PubMed ID: 33332261
[TBL] [Abstract][Full Text] [Related]
6. From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.
Aguado MT; Jodar L; Granoff D; Rabinovich R; Ceccarini C; Perkin GW
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S391-5. PubMed ID: 26553665
[TBL] [Abstract][Full Text] [Related]
7. Impact of serogroup A meningococcal conjugate vaccine for Africa.
Stuart JM
Hum Vaccin Immunother; 2018 May; 14(5):1116-1117. PubMed ID: 29194010
[TBL] [Abstract][Full Text] [Related]
8. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
[TBL] [Abstract][Full Text] [Related]
9. Technical Development of a New Meningococcal Conjugate Vaccine.
Frasch CE; Kapre SV; Lee CH; Préaud JM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S404-9. PubMed ID: 26553667
[TBL] [Abstract][Full Text] [Related]
10. Serogroup A meningococcal conjugate vaccines in Africa.
Kristiansen PA; Jørgensen HJ; Caugant DA
Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
[TBL] [Abstract][Full Text] [Related]
11. Narrative review of methods and findings of recent studies on the carriage of meningococci and other Neisseria species in the African Meningitis Belt.
Greenwood BM; Aseffa A; Caugant DA; Diallo K; Kristiansen PA; Maiden MCJ; Stuart JM; Trotter CL
Trop Med Int Health; 2019 Feb; 24(2):143-154. PubMed ID: 30461138
[TBL] [Abstract][Full Text] [Related]
12. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.
LaForce FM; Djingarey M; Viviani S; Preziosi MP
Hum Vaccin Immunother; 2018 May; 14(5):1098-1102. PubMed ID: 28968148
[TBL] [Abstract][Full Text] [Related]
13. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt.
Carod Artal FJ
Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213
[TBL] [Abstract][Full Text] [Related]
14. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.
Kristiansen PA; Ba AK; Ouédraogo AS; Sanou I; Ouédraogo R; Sangaré L; Diomandé F; Kandolo D; Saga IM; Misegades L; Clark TA; Préziosi MP; Caugant DA
BMC Infect Dis; 2014 Dec; 14():663. PubMed ID: 25472422
[TBL] [Abstract][Full Text] [Related]
15. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448
[TBL] [Abstract][Full Text] [Related]
16. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
Xie O; Pollard AJ; Mueller JE; Norheim G
Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
[TBL] [Abstract][Full Text] [Related]
17. Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011-2017.
Fernandez K; Lingani C; Aderinola OM; Goumbi K; Bicaba B; Edea ZA; Glèlè C; Sarkodie B; Tamekloe A; Ngomba A; Djingarey M; Bwaka A; Perea W; Ronveaux O
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S225-S232. PubMed ID: 31671449
[TBL] [Abstract][Full Text] [Related]
18. Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines.
Alderson MR; LaForce FM; Sobanjo-Ter Meulen A; Hwang A; Preziosi MP; Klugman KP
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S274-S278. PubMed ID: 31671447
[TBL] [Abstract][Full Text] [Related]
19. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.
Trotter CL; Cibrelus L; Fernandez K; Lingani C; Ronveaux O; Stuart JM
Vaccine; 2015 Nov; 33(46):6212-7. PubMed ID: 26463444
[TBL] [Abstract][Full Text] [Related]
20. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.
Marc LaForce F; Ravenscroft N; Djingarey M; Viviani S
Vaccine; 2009 Jun; 27 Suppl 2():B13-9. PubMed ID: 19477559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
